Adverse Reactions Chemotherapy FDA Immunization 
pharmaphorum
JANUARY 26, 2022
The FDA has placed a partial clinical fold on clinical trials of Gilead Sciences’ magrolimab, the centre piece of its $4.9 Other research suggests it my also play downgrade immune responses by cell-killing T cells as well as dendritic cells, which are involved in antibody responses, making it a compelling target for drug developers.
European Pharmaceutical Review
DECEMBER 27, 2023
Bridging therapy has been shown to correlate with an inferior response to CAR T-cell therapy due to both progression of the chemotherapy-refractory malignant disease during the manufacturing period and increased toxicity. After this incident CAR-related toxicity scales and guidelines were established to prevent adverse reactions.
Expert insights. Personalized for you.
40 
Let's personalize your content